<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a subset of patients with <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>), symptoms persist in spite of <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> (<z:chebi fb="4" ids="53266">PPI</z:chebi>) therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Endoscopic gastroplication (EG) was reported to provide a novel therapeutic option in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>To evaluate symptomatic and objective outcome of EG in <z:chebi fb="4" ids="53266">PPI</z:chebi> refractory <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, consecutive <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients with persisting reflux symptoms during at least 2 months double dose <z:chebi fb="4" ids="53266">PPI</z:chebi> were recruited for EG (Endocinch) </plain></SENT>
<SENT sid="3" pm="."><plain>Exclusion criteria were high-grade <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo>, and <z:hpo ids='HP_0002036'>hiatal hernia</z:hpo> &gt; 3 cm </plain></SENT>
<SENT sid="4" pm="."><plain>Symptoms and <z:chebi fb="4" ids="53266">PPI</z:chebi> use were evaluated before and 1, 3, and 12 months after the EG; 24-hr pH monitoring off <z:chebi fb="4" ids="53266">PPI</z:chebi> was performed before and after 3 and 12 months </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> data are given as mean +/- SD and were analyzed by Student's t test </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty patients (10 females; mean age, 45 +/- 11 years) were recruited </plain></SENT>
<SENT sid="7" pm="."><plain>Under conscious sedation with midazolam (6 +/- 2 mg) and pethidine (53 +/- 5 mg), a mean of 2.0 +/- 0.2 sutures was applied during a procedure time of 33 +/- 6 min </plain></SENT>
<SENT sid="8" pm="."><plain>Throat ache and mild epigastric pain for up to 3 days after the procedure were the only adverse events </plain></SENT>
<SENT sid="9" pm="."><plain>At 3 and 12 months symptom score (11.6 +/- 6 vs. 6.4 +/- 3.7 [P &lt; 0.01] and 7.1 +/- 4.5 [P &lt; 0.05]) as well as pH monitoring (% time pH &lt; 4: 17.0 +/- 11.1 vs. 8.1 +/- 5.7% [P &lt; 0.01] and 9.8 +/- 4.1% [P &lt; 0.01]) significantly improved </plain></SENT>
<SENT sid="10" pm="."><plain>Ph monitoring was normalized (&lt; 4% of time) in seven patients after 3 months </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="4" ids="53266">PPIs</z:chebi> could be stopped in 13 patients, with 2 patients still using H2-blockers and 1 using cisapride after 3 months </plain></SENT>
<SENT sid="12" pm="."><plain>After 12 months only six patients were free of <z:chebi fb="4" ids="53266">PPI</z:chebi> use and pH monitoring was normalized in six patients </plain></SENT>
<SENT sid="13" pm="."><plain>We conclude that EG provides short- and medium-term symptomatic and objective relief to a subset of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> patients refractory to high-dose <z:chebi fb="4" ids="53266">PPI</z:chebi> </plain></SENT>
</text></document>